Researchers will be excited to learn about the do-it-all Ceveron® s100, for automated hemostasis research assays including ADAMTS13, FXIII, and Thrombin Generation Testing. You name it, Ceveron® s100 can do it! For research use only in the U.S. and Canada. Not for use in diagnostic procedures.
Explore the leading edge in impaired primary hemostasis assessment with T-TAS® 01 – get results quickly with whole blood using an automated microchip flow chamber system developed for the quantitative assessment of the thrombus formation process under physiologic flow conditions. The test requires few steps to run, minimal pre-analytical handling, small sample volume, and a simple to interpret numerical cut-off makes for a simple and reliable identification of patients with a primary hemostatic disorder or to measure the efficacy of any anti-platelet therapeutic in ten minutes or less from assay start. The T-TAS® 01 is for the global evaluation of overall hemostatic ability using physiologic flow conditions, and is sensitive to both aspirin and P2Y12 inhibition, as well as the various vWD subtypes and Glanzmann Thrombasthenia. Separate reagent kit or addition of exogenous agonists aren’t necessary.
DiaPharma delivers solutions by providing strong personal support with technical competence and experience to ensure customer expectations will be met or exceeded. Our strength is grounded in both science and staff. For more than 20 years, DiaPharma has been proud to give each of our customers a truly personalized experience—a focused, dedicated resource that understands our customers’ needs, and has the scientific and technical expertise to help customers make the best product choices. It’s Not Just Support. It’s Solutions.